SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '0XZ'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1BRP_A_RTLA183_0 (RETINOL BINDING PROTEIN)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	PHE A 438 ALA A 177 MET A 227 MET A 281 LEU A 213	0XZ A 501 (-4.8A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 (-3.5A) None	1.34A	1brpA-4gv1A: undetectable	1brpA-4gv1A: 21.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1FMO_E_ADNE351_1 (CAMP-DEPENDENT PROTEIN KINASE)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 GLU A 234 ASN A 279 THR A 291 PHE A 438	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 505 ( 2.9A) 0XZ A 501 ( 4.5A) 0XZ A 501 ( 4.1A) 0XZ A 501 (-4.8A)	0.70A	1fmoE-4gv1A: 40.8	1fmoE-4gv1A: 39.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUO_A_ADNA1_1 (AURORA-RELATED KINASE 1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 9	LEU A 156 GLY A 157 VAL A 164 ALA A 177 TYR A 229 ALA A 230	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A)	0.59A	1muoA-4gv1A: 9.6	1muoA-4gv1A: 31.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 6	LEU A 156 LYS A 179 VAL A 201 ARG A 273	0XZ A 501 ( 4.1A) GOL A 503 ( 2.8A) None TPO A 308 ( 2.9A)	1.07A	1opjB-4gv1A: 20.7	1opjB-4gv1A: 26.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 9	LEU A 156 VAL A 164 ALA A 177 MET A 227 ALA A 230 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 (-3.7A) None	0.68A	1xbbA-4gv1A: 23.5	1xbbA-4gv1A: 24.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EVA_A_ADNA498_1 (TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 11	GLY A 157 VAL A 164 ALA A 177 MET A 227 TYR A 229 ALA A 230 ASP A 292	GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A) 0XZ A 501 ( 3.4A)	0.53A	2evaA-4gv1A: 23.0	2evaA-4gv1A: 28.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_A_MIXA539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 ASP A 274 LYS A 276 ASN A 279 MET A 281	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) None 0XZ A 501 ( 4.4A) 0XZ A 501 ( 4.5A) 0XZ A 501 (-3.5A)	0.90A	2fumA-4gv1A: 26.7	2fumA-4gv1A: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_B_MIXB1539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 MET A 227 TYR A 229 LYS A 276 ASN A 279 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 ( 4.4A) 0XZ A 501 ( 4.5A) 0XZ A 501 ( 3.4A)	0.75A	2fumB-4gv1A: 26.7	2fumB-4gv1A: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_B_MIXB1539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 MET A 227 TYR A 229 LYS A 276 ASN A 279 MET A 281	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 ( 4.4A) 0XZ A 501 ( 4.5A) 0XZ A 501 (-3.5A)	0.82A	2fumB-4gv1A: 26.7	2fumB-4gv1A: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_C_MIXC2539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 MET A 227 TYR A 229 MET A 281 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.5A) 0XZ A 501 ( 3.4A)	0.87A	2fumC-4gv1A: 25.4	2fumC-4gv1A: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_C_MIXC2539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 156 VAL A 164 ALA A 177 MET A 227 TYR A 229 ASN A 279 MET A 281 ASP A 292	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 ( 4.5A) 0XZ A 501 (-3.5A) 0XZ A 501 ( 3.4A)	0.86A	2fumC-4gv1A: 25.4	2fumC-4gv1A: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_D_MIXD3539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 MET A 227 LYS A 276 ASN A 279 MET A 281 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.4A) 0XZ A 501 ( 4.5A) 0XZ A 501 (-3.5A) 0XZ A 501 ( 3.4A)	0.86A	2fumD-4gv1A: 25.4	2fumD-4gv1A: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2IVU_A_ZD6A3015_0 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	9 / 12	LEU A 156 GLY A 157 VAL A 164 LYS A 179 GLU A 198 LEU A 202 TYR A 229 ALA A 230 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A) 0XZ A 501 ( 3.4A)	0.54A	2ivuA-4gv1A: 25.6	2ivuA-4gv1A: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	GLY A 157 VAL A 164 ALA A 177 TYR A 229 GLY A 233 MET A 281	GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 4.9A) None 0XZ A 501 (-3.5A)	0.63A	2wgjA-4gv1A: 21.5	2wgjA-4gv1A: 24.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LXK_A_MI1A1125_1 (TYROSINE-PROTEIN KINASE JAK3)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 LYS A 179 MET A 227 TYR A 229	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A)	0.69A	3lxkA-4gv1A: 23.7	3lxkA-4gv1A: 27.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_1 (CYCLIN-DEPENDENT KINASE 8)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	VAL A 164 ALA A 177 GLU A 198 LEU A 202 TYR A 229 ALA A 230 LEU A 264	0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 (-3.6A) None 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A) None	0.87A	3rgfA-4gv1A: 22.7	3rgfA-4gv1A: 25.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3V5W_A_8PRA701_1 (G-PROTEIN COUPLED RECEPTOR KINASE 2)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	GLY A 159 GLY A 162 VAL A 164 ALA A 177 LYS A 179 LEU A 181 ASP A 292	0XZ A 501 (-4.1A) 0XZ A 501 (-3.8A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-4.9A) 0XZ A 501 ( 3.4A)	0.71A	3v5wA-4gv1A: 12.4	3v5wA-4gv1A: 22.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 156 VAL A 164 ALA A 177 GLU A 198 LEU A 202 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 (-3.6A) None None	0.61A	3wzdA-4gv1A: 20.7	3wzdA-4gv1A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WZE_A_BAXA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLU A 198 LEU A 202 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None None	0.62A	3wzeA-4gv1A: 21.2	3wzeA-4gv1A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AGC_A_AXIA2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLU A 198 LEU A 202 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None None	0.67A	4agcA-4gv1A: 20.6	4agcA-4gv1A: 23.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	MET A 227 ASP A 274 LYS A 276 ASN A 279 ASP A 292 VAL A 201	0XZ A 501 (-3.8A) None 0XZ A 501 ( 4.4A) 0XZ A 501 ( 4.5A) 0XZ A 501 ( 3.4A) None	1.19A	4an2A-4gv1A: 25.3	4an2A-4gv1A: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ASD_A_BAXA1500_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLU A 198 LEU A 202 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None None	0.58A	4asdA-4gv1A: 20.8	4asdA-4gv1A: 23.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CKJ_A_ADNA2014_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 10	LEU A 156 GLY A 157 GLY A 159 VAL A 164 ALA A 177 TYR A 229 ALA A 230	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A)	0.32A	4ckjA-4gv1A: 26.2	4ckjA-4gv1A: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLY A 233 THR A 291 ASP A 292	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) None 0XZ A 501 ( 4.1A) 0XZ A 501 ( 3.4A)	0.97A	4hjoA-4gv1A: 21.2	4hjoA-4gv1A: 23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4I22_A_IREA9001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	LEU A 156 GLY A 157 VAL A 164 ALA A 177 MET A 227 GLY A 233 THR A 291 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) None 0XZ A 501 ( 4.1A) 0XZ A 501 ( 3.4A)	0.87A	4i22A-4gv1A: 20.5	4i22A-4gv1A: 24.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4O0S_A_ADNA500_1 (AURORA KINASE A)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 11	LEU A 156 GLY A 157 VAL A 164 ALA A 177 LYS A 179 ASN A 279 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) 0XZ A 501 ( 4.5A) 0XZ A 501 ( 3.4A)	0.58A	4o0sA-4gv1A: 32.6	4o0sA-4gv1A: 31.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4O0W_A_ADNA501_1 (AURORA KINASE A)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	4 / 6	LEU A 156 GLY A 157 VAL A 164 ALA A 177	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A)	0.25A	4o0wA-4gv1A: 31.2	4o0wA-4gv1A: 31.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OTI_A_MI1A1001_1 (SERINE/THREONINE-PRO TEIN KINASE N1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 GLY A 157 GLY A 159 GLY A 162 VAL A 164 ALA A 177 PHE A 438	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.1A) 0XZ A 501 (-3.8A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-4.8A)	0.59A	4otiA-4gv1A: 36.0	4otiA-4gv1A: 46.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OTI_A_MI1A1001_1 (SERINE/THREONINE-PRO TEIN KINASE N1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 GLY A 157 GLY A 162 VAL A 164 ALA A 177 ASP A 292 PHE A 438	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-3.8A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 3.4A) 0XZ A 501 (-4.8A)	0.50A	4otiA-4gv1A: 36.0	4otiA-4gv1A: 46.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4OTI_A_MI1A1001_1 (SERINE/THREONINE-PRO TEIN KINASE N1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 GLY A 157 GLY A 162 VAL A 164 ALA A 177 LYS A 179 ASP A 292	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-3.8A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) 0XZ A 501 ( 3.4A)	0.53A	4otiA-4gv1A: 36.0	4otiA-4gv1A: 46.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QMZ_A_B49A401_1 (SERINE/THREONINE-PRO TEIN KINASE 24)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	GLY A 157 VAL A 164 ALA A 177 THR A 211 MET A 227 TYR A 229	GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 4.0A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A)	0.43A	4qmzA-4gv1A: 30.1	4qmzA-4gv1A: 30.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4V01_B_0LIB1770_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 9	LEU A 156 VAL A 164 LYS A 179 TYR A 229 ARG A 273 ILE A 290	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) 0XZ A 501 ( 4.9A) TPO A 308 ( 2.9A) None	0.84A	4v01B-4gv1A: 21.2	4v01B-4gv1A: 23.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 12	VAL A 164 ALA A 177 LYS A 179 LEU A 202 PHE A 293	0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) None None	0.81A	5cswA-4gv1A: 21.1	5cswA-4gv1A: 26.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5HES_B_032B401_1 (MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	VAL A 164 ALA A 177 LYS A 179 TYR A 229 ALA A 230 PHE A 293	0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A) None	0.80A	5hesB-4gv1A: 21.6	5hesB-4gv1A: 24.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5IZJ_F_AZ1F2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR-DAR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 7	GLY A 157 GLY A 159 GLY A 162 VAL A 164 LEU A 181	GOL A 505 ( 3.4A) 0XZ A 501 (-4.1A) 0XZ A 501 (-3.8A) 0XZ A 501 (-4.5A) GOL A 503 (-4.9A)	0.29A	5izjB-4gv1A: 37.5	5izjB-4gv1A: 38.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5IZJ_G_AZ1G2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 7	GLY A 157 GLY A 159 VAL A 164 LYS A 179 LEU A 181	GOL A 505 ( 3.4A) 0XZ A 501 (-4.1A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) GOL A 503 (-4.9A)	0.39A	5izjA-4gv1A: 39.3	5izjA-4gv1A: 38.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5J5X_B_AZ1B2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAL-DAR-DAR- DAR-DAR)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 7	GLY A 157 GLY A 159 VAL A 164 LYS A 179 ASP A 292	GOL A 505 ( 3.4A) 0XZ A 501 (-4.1A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) 0XZ A 501 ( 3.4A)	0.66A	5j5xA-4gv1A: 41.3	5j5xA-4gv1A: 38.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5LVN_A_ADNA402_1 (3-PHOSPHOINOSITIDE-D EPENDENT PROTEIN KINASE 1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 11	LEU A 156 GLY A 157 VAL A 164 ALA A 177 TYR A 229 ALA A 230 GLU A 234	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A) GOL A 505 ( 2.9A)	0.35A	5lvnA-4gv1A: 36.2	5lvnA-4gv1A: 31.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MAF_A_XINA403_1 (MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	8 / 12	GLY A 157 VAL A 164 ALA A 177 LYS A 179 GLU A 198 TYR A 229 GLY A 233 GLU A 234	GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) 0XZ A 501 ( 4.9A) None GOL A 505 ( 2.9A)	0.44A	5mafA-4gv1A: 30.7	5mafA-4gv1A: 11.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_1 (TYROSINE-PROTEIN KINASE ABL1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 10	LEU A 156 VAL A 164 LYS A 179 GLU A 198 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None	0.61A	5mo4A-4gv1A: 18.2	5mo4A-4gv1A: 22.11
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5N3H_A_NCAA401_0 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 10	LEU A 156 VAL A 164 ALA A 177 MET A 227 TYR A 229 THR A 291 PHE A 438	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) 0XZ A 501 ( 4.9A) 0XZ A 501 ( 4.1A) 0XZ A 501 (-4.8A)	0.51A	5n3hA-4gv1A: 41.5	5n3hA-4gv1A: 39.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_1 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 12	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLU A 198 GLY A 232	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None	0.70A	5vcyA-4gv1A: 24.5	5vcyA-4gv1A: 25.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 9	ALA A 177 MET A 227 GLY A 232 MET A 281 THR A 291	0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) None 0XZ A 501 (-3.5A) 0XZ A 501 ( 4.1A)	1.06A	5w5vA-4gv1A: 4.5	5w5vA-4gv1A: 20.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	5 / 9	LEU A 156 ALA A 177 GLY A 233 MET A 281 THR A 211	0XZ A 501 ( 4.1A) 0XZ A 501 (-3.3A) None 0XZ A 501 (-3.5A) 0XZ A 501 ( 4.0A)	1.26A	5w5vA-4gv1A: 4.5	5w5vA-4gv1A: 20.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	6 / 9	LEU A 156 ALA A 177 MET A 227 GLY A 233 MET A 281 THR A 291	0XZ A 501 ( 4.1A) 0XZ A 501 (-3.3A) 0XZ A 501 (-3.8A) None 0XZ A 501 (-3.5A) 0XZ A 501 ( 4.1A)	0.84A	5w5vA-4gv1A: 4.5	5w5vA-4gv1A: 20.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 GLU A 198 TYR A 229 ALA A 230 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 (-3.6A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A) None	0.59A	5zv2A-4gv1A: 20.7	5zv2A-4gv1A: 13.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	7 / 12	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLU A 198 ALA A 230 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) 0XZ A 501 (-3.7A) None	0.65A	5zv2B-4gv1A: 20.8	5zv2B-4gv1A: 13.96

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1BRP_A_RTLA183_0","RETINOL BINDING PROTEIN","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"PHE A 438;ALA A 177;MET A 227;MET A 281;LEU A 213","0XZ A 501 (-4.8A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 (-3.5A);None","1.34A","1brpA-4gv1A:undetectable",null],["1FMO_E_ADNE351_1","CAMP-DEPENDENT PROTEIN KINASE","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;GLU A 234;ASN A 279;THR A 291;PHE A 438","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 505 ( 2.9A);0XZ A 501 ( 4.5A);0XZ A 501 ( 4.1A);0XZ A 501 (-4.8A)","0.70A","1fmoE-4gv1A:40.8","1brpA-4gv1A:21.33"],["1MUO_A_ADNA1_1","AURORA-RELATED KINASE 1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;TYR A 229;ALA A 230","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A)","0.59A","1muoA-4gv1A:9.6","1fmoE-4gv1A:39.40"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"LEU A 156;LYS A 179;VAL A 201;ARG A 273","0XZ A 501 ( 4.1A);GOL A 503 ( 2.8A);None;TPO A 308 ( 2.9A)","1.07A","1opjB-4gv1A:20.7","1muoA-4gv1A:31.05"],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A 156;VAL A 164;ALA A 177;MET A 227;ALA A 230;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 (-3.7A);None","0.68A","1xbbA-4gv1A:23.5","1opjB-4gv1A:26.46"],["2EVA_A_ADNA498_1","TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"GLY A 157;VAL A 164;ALA A 177;MET A 227;TYR A 229;ALA A 230;ASP A 292","GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A);0XZ A 501 ( 3.4A)","0.53A","2evaA-4gv1A:23.0","1xbbA-4gv1A:24.64"],["2FUM_A_MIXA539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;ASP A 274;LYS A 276;ASN A 279;MET A 281","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);None;0XZ A 501 ( 4.4A);0XZ A 501 ( 4.5A);0XZ A 501 (-3.5A)","0.90A","2fumA-4gv1A:26.7","2evaA-4gv1A:28.33"],["2FUM_B_MIXB1539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;MET A 227;TYR A 229;LYS A 276;ASN A 279;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A);0XZ A 501 ( 4.4A);0XZ A 501 ( 4.5A);0XZ A 501 ( 3.4A)","0.75A","2fumB-4gv1A:26.7","2fumA-4gv1A:24.31"],["2FUM_B_MIXB1539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;MET A 227;TYR A 229;LYS A 276;ASN A 279;MET A 281","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A);0XZ A 501 ( 4.4A);0XZ A 501 ( 4.5A);0XZ A 501 (-3.5A)","0.82A","2fumB-4gv1A:26.7","2fumB-4gv1A:24.31"],["2FUM_C_MIXC2539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;MET A 227;TYR A 229;MET A 281;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.5A);0XZ A 501 ( 3.4A)","0.87A","2fumC-4gv1A:25.4","2fumB-4gv1A:24.31"],["2FUM_C_MIXC2539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A 156;VAL A 164;ALA A 177;MET A 227;TYR A 229;ASN A 279;MET A 281;ASP A 292","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A);0XZ A 501 ( 4.5A);0XZ A 501 (-3.5A);0XZ A 501 ( 3.4A)","0.86A","2fumC-4gv1A:25.4","2fumC-4gv1A:24.31"],["2FUM_D_MIXD3539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;MET A 227;LYS A 276;ASN A 279;MET A 281;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.4A);0XZ A 501 ( 4.5A);0XZ A 501 (-3.5A);0XZ A 501 ( 3.4A)","0.86A","2fumD-4gv1A:25.4","2fumC-4gv1A:24.31"],["2IVU_A_ZD6A3015_0","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET PRECURSOR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",9,"LEU A 156;GLY A 157;VAL A 164;LYS A 179;GLU A 198;LEU A 202;TYR A 229;ALA A 230;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None;0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A);0XZ A 501 ( 3.4A)","0.54A","2ivuA-4gv1A:25.6","2fumD-4gv1A:24.31"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"GLY A 157;VAL A 164;ALA A 177;TYR A 229;GLY A 233;MET A 281","GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 4.9A);None;0XZ A 501 (-3.5A)","0.63A","2wgjA-4gv1A:21.5","2ivuA-4gv1A:27.01"],["3LXK_A_MI1A1125_1","TYROSINE-PROTEIN KINASE JAK3","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;LYS A 179;MET A 227;TYR A 229","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A)","0.69A","3lxkA-4gv1A:23.7","2wgjA-4gv1A:24.79"],["3RGF_A_BAXA465_1","CYCLIN-DEPENDENT KINASE 8","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"VAL A 164;ALA A 177;GLU A 198;LEU A 202;TYR A 229;ALA A 230;LEU A 264","0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 (-3.6A);None;0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A);None","0.87A","3rgfA-4gv1A:22.7","3lxkA-4gv1A:27.88"],["3V5W_A_8PRA701_1","G-PROTEIN COUPLED RECEPTOR KINASE 2","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"GLY A 159;GLY A 162;VAL A 164;ALA A 177;LYS A 179;LEU A 181;ASP A 292","0XZ A 501 (-4.1A);0XZ A 501 (-3.8A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-4.9A);0XZ A 501 ( 3.4A)","0.71A","3v5wA-4gv1A:12.4","3rgfA-4gv1A:25.37"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A 156;VAL A 164;ALA A 177;GLU A 198;LEU A 202;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 (-3.6A);None;None","0.61A","3wzdA-4gv1A:20.7","3v5wA-4gv1A:22.83"],["3WZE_A_BAXA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLU A 198;LEU A 202;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None;None","0.62A","3wzeA-4gv1A:21.2","3wzdA-4gv1A:26.25"],["4AGC_A_AXIA2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLU A 198;LEU A 202;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None;None","0.67A","4agcA-4gv1A:20.6","3wzeA-4gv1A:26.25"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"MET A 227;ASP A 274;LYS A 276;ASN A 279;ASP A 292;VAL A 201","0XZ A 501 (-3.8A);None;0XZ A 501 ( 4.4A);0XZ A 501 ( 4.5A);0XZ A 501 ( 3.4A);None","1.19A","4an2A-4gv1A:25.3","4agcA-4gv1A:23.20"],["4ASD_A_BAXA1500_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLU A 198;LEU A 202;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None;None","0.58A","4asdA-4gv1A:20.8","4an2A-4gv1A:25.60"],["4CKJ_A_ADNA2014_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;GLY A 159;VAL A 164;ALA A 177;TYR A 229;ALA A 230","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A)","0.32A","4ckjA-4gv1A:26.2","4asdA-4gv1A:23.20"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLY A 233;THR A 291;ASP A 292","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);None;0XZ A 501 ( 4.1A);0XZ A 501 ( 3.4A)","0.97A","4hjoA-4gv1A:21.2","4ckjA-4gv1A:27.01"],["4I22_A_IREA9001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;MET A 227;GLY A 233;THR A 291;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);None;0XZ A 501 ( 4.1A);0XZ A 501 ( 3.4A)","0.87A","4i22A-4gv1A:20.5","4hjoA-4gv1A:23.86"],["4O0S_A_ADNA500_1","AURORA KINASE A","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;LYS A 179;ASN A 279;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);0XZ A 501 ( 4.5A);0XZ A 501 ( 3.4A)","0.58A","4o0sA-4gv1A:32.6","4i22A-4gv1A:24.38"],["4O0W_A_ADNA501_1","AURORA KINASE A","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",4,"LEU A 156;GLY A 157;VAL A 164;ALA A 177","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A)","0.25A","4o0wA-4gv1A:31.2","4o0sA-4gv1A:31.20"],["4OTI_A_MI1A1001_1","SERINE\/THREONINE-PROTEIN KINASE N1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;GLY A 159;GLY A 162;VAL A 164;ALA A 177;PHE A 438","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.1A);0XZ A 501 (-3.8A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-4.8A)","0.59A","4otiA-4gv1A:36.0","4o0wA-4gv1A:31.49"],["4OTI_A_MI1A1001_1","SERINE\/THREONINE-PROTEIN KINASE N1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;GLY A 162;VAL A 164;ALA A 177;ASP A 292;PHE A 438","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-3.8A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 3.4A);0XZ A 501 (-4.8A)","0.50A","4otiA-4gv1A:36.0","4otiA-4gv1A:46.36"],["4OTI_A_MI1A1001_1","SERINE\/THREONINE-PROTEIN KINASE N1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;GLY A 162;VAL A 164;ALA A 177;LYS A 179;ASP A 292","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-3.8A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);0XZ A 501 ( 3.4A)","0.53A","4otiA-4gv1A:36.0","4otiA-4gv1A:46.36"],["4QMZ_A_B49A401_1","SERINE\/THREONINE-PROTEIN KINASE 24","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"GLY A 157;VAL A 164;ALA A 177;THR A 211;MET A 227;TYR A 229","GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 4.0A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A)","0.43A","4qmzA-4gv1A:30.1","4otiA-4gv1A:46.36"],["4V01_B_0LIB1770_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A 156;VAL A 164;LYS A 179;TYR A 229;ARG A 273;ILE A 290","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);0XZ A 501 ( 4.9A);TPO A 308 ( 2.9A);None","0.84A","4v01B-4gv1A:21.2","4qmzA-4gv1A:30.66"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"VAL A 164;ALA A 177;LYS A 179;LEU A 202;PHE A 293","0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);None;None","0.81A","5cswA-4gv1A:21.1","4v01B-4gv1A:23.42"],["5HES_B_032B401_1","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"VAL A 164;ALA A 177;LYS A 179;TYR A 229;ALA A 230;PHE A 293","0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A);None","0.80A","5hesB-4gv1A:21.6","5cswA-4gv1A:26.33"],["5IZJ_F_AZ1F2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR-DAR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"GLY A 157;GLY A 159;GLY A 162;VAL A 164;LEU A 181","GOL A 505 ( 3.4A);0XZ A 501 (-4.1A);0XZ A 501 (-3.8A);0XZ A 501 (-4.5A);GOL A 503 (-4.9A)","0.29A","5izjB-4gv1A:37.5","5hesB-4gv1A:24.36"],["5IZJ_G_AZ1G2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"GLY A 157;GLY A 159;VAL A 164;LYS A 179;LEU A 181","GOL A 505 ( 3.4A);0XZ A 501 (-4.1A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);GOL A 503 (-4.9A)","0.39A","5izjA-4gv1A:39.3","5izjB-4gv1A:38.24"],["5J5X_B_AZ1B2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAL-DAR-DAR-DAR-DAR","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"GLY A 157;GLY A 159;VAL A 164;LYS A 179;ASP A 292","GOL A 505 ( 3.4A);0XZ A 501 (-4.1A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);0XZ A 501 ( 3.4A)","0.66A","5j5xA-4gv1A:41.3","5izjA-4gv1A:38.24"],["5LVN_A_ADNA402_1","3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;TYR A 229;ALA A 230;GLU A 234","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A);GOL A 505 ( 2.9A)","0.35A","5lvnA-4gv1A:36.2","5j5xA-4gv1A:38.24"],["5MAF_A_XINA403_1","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",8,"GLY A 157;VAL A 164;ALA A 177;LYS A 179;GLU A 198;TYR A 229;GLY A 233;GLU A 234","GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);0XZ A 501 ( 4.9A);None;GOL A 505 ( 2.9A)","0.44A","5mafA-4gv1A:30.7","5lvnA-4gv1A:31.51"],["5MO4_A_NILA601_1","TYROSINE-PROTEIN KINASE ABL1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A 156;VAL A 164;LYS A 179;GLU A 198;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None","0.61A","5mo4A-4gv1A:18.2","5mafA-4gv1A:11.70"],["5N3H_A_NCAA401_0","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;MET A 227;TYR A 229;THR A 291;PHE A 438","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);0XZ A 501 ( 4.9A);0XZ A 501 ( 4.1A);0XZ A 501 (-4.8A)","0.51A","5n3hA-4gv1A:41.5","5mo4A-4gv1A:22.11"],["5VCY_A_DB8A401_1","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLU A 198;GLY A 232","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None","0.70A","5vcyA-4gv1A:24.5","5n3hA-4gv1A:39.35"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"ALA A 177;MET A 227;GLY A 232;MET A 281;THR A 291","0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);None;0XZ A 501 (-3.5A);0XZ A 501 ( 4.1A)","1.06A","5w5vA-4gv1A:4.5","5vcyA-4gv1A:25.68"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",5,"LEU A 156;ALA A 177;GLY A 233;MET A 281;THR A 211","0XZ A 501 ( 4.1A);0XZ A 501 (-3.3A);None;0XZ A 501 (-3.5A);0XZ A 501 ( 4.0A)","1.26A","5w5vA-4gv1A:4.5","5w5vA-4gv1A:20.43"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",6,"LEU A 156;ALA A 177;MET A 227;GLY A 233;MET A 281;THR A 291","0XZ A 501 ( 4.1A);0XZ A 501 (-3.3A);0XZ A 501 (-3.8A);None;0XZ A 501 (-3.5A);0XZ A 501 ( 4.1A)","0.84A","5w5vA-4gv1A:4.5","5w5vA-4gv1A:20.43"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;GLU A 198;TYR A 229;ALA A 230;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 (-3.6A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A);None","0.59A","5zv2A-4gv1A:20.7","5w5vA-4gv1A:20.43"],["5ZV2_B_LEVB801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","4gv1","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","Homo sapiens",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLU A 198;ALA A 230;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);0XZ A 501 (-3.7A);None","0.65A","5zv2B-4gv1A:20.8","5zv2A-4gv1A:13.96"]]